Zobrazeno 1 - 10
of 180
pro vyhledávání: '"Guillermo, Villacampa"'
Autor:
Sonia Pernas, Esther Sanfeliu, Guillermo Villacampa, Javier Salvador, Antonia Perelló, Xavier González, Begoña Jiménez, María Merino, Patricia Palacios, Tomás Pascual, Emilio Alba, Lorea Villanueva, Samyukta Chillara, Juan Manuel Ferrero-Cafiero, Patricia Galvan, Aleix Prat, Eva Ciruelos
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-8 (2024)
Abstract With the incorporation of cyclin-dependent kinase inhibitors in early breast cancer (BC), a better identification of biomarkers is needed. The PROMETEO II trial aimed to evaluate the antitumor activity of palbociclib plus letrozole and to id
Externí odkaz:
https://doaj.org/article/78438f11a5ef4e73bef2803507ca9c9e
Autor:
Gloria Iacoboni, Víctor Navarro, Pierre Sesques, Kai Rejeski, Mariana Bastos-Oreiro, Fabio Serpenti, Ana Africa Martin Lopez, Josu Iraola-Truchuelo, Javier Delgado, Ariadna Perez, Manuel Guerreiro, Ana Carolina Caballero, Nuria Martinez-Cibrian, Hugo Luzardo Henriquez, Jose Maria Sanchez Pina, Juan-Manuel Sancho, Hervé Ghesquieres, Alberto Mussetti, Lucia Lopez Corral, Rafael Hernani, Juan Luis Reguera, Anna Sureda, Francesc Bosch, Alejandro Martin Garcia-Sancho, Mi Kwon, Marion Subklewe, Andrea Kuhnl, Emmanuel Bachy, Pere Barba, Guillermo Villacampa, Pau Abrisqueta
Publikováno v:
Journal of Hematology & Oncology, Vol 17, Iss 1, Pp 1-10 (2024)
Abstract Chimeric antigen receptor (CAR) T-cell therapy fails to achieve durable responses in over 60% of relapsed/refractory (R/R) large B-cell lymphoma (LBCL) patients in the third or later line setting. After CAR-T failure, survival outcomes are h
Externí odkaz:
https://doaj.org/article/7a33c510abd6496482324ad69e68ca9f
Autor:
Fara Brasó-Maristany, Juan Manuel Ferrero-Cafiero, Claudette Falato, Olga Martínez-Sáez, Juan Miguel Cejalvo, Mireia Margelí, Pablo Tolosa, Francisco Javier Salvador-Bofill, Josefina Cruz, Blanca González-Farré, Esther Sanfeliu, Andreu Òdena, Violeta Serra, Francisco Pardo, Ana María Luna Barrera, Miriam Arumi, Juan Antonio Guerra, Guillermo Villacampa, Rodrigo Sánchez-Bayona, Eva Ciruelos, Martín Espinosa-Bravo, Yann Izarzugaza, Patricia Galván, Judith Matito, Sonia Pernas, Maria Vidal, Anu Santhanagopal, Dalila Sellami, Stephen Esker, Pang-Dian Fan, Fumitaka Suto, Ana Vivancos, Tomás Pascual, Aleix Prat, Mafalda Oliveira
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-13 (2024)
Abstract Patritumab deruxtecan (HER3-DXd) exhibits promising efficacy in breast cancer, with its activity not directly correlated to baseline ERBB3/HER3 levels. This research investigates the genetic factors affecting HER3-DXd’s response in women w
Externí odkaz:
https://doaj.org/article/7c7d4486147e4021ad5651e0e2b54a88
Autor:
Oriol Mirallas, Berta Martin-Cullell, Víctor Navarro, Kreina Sharela Vega, Jordi Recuero-Borau, Diego Gómez-Puerto, Daniel López-Valbuena, Clara Salva de Torres, Laura Andurell, Anna Pedrola, Roger Berché, Fiorella Palmas, José María Ucha, Guillermo Villacampa, Alejandra Rezqallah, Judit Sanz-Beltran, Rafael Bach, Sergio Bueno, Cristina Viaplana, Gaspar Molina, Alberto Hernando-Calvo, Juan Aguilar-Company, María Roca, Eva Muñoz-Couselo, Alex Martínez-Martí, Ada Alonso, Simeon Eremiev, Teresa Macarulla, Ana Oaknin, Cristina Saura, Elena Élez, Enriqueta Felip, Ángeles Peñuelas, Rosa Burgos, Patricia Gómez Pardo, Elena Garralda, Josep Tabernero, Sònia Serradell, Sònia Servitja, David Paez, Rodrigo Dienstmann, Joan Carles
Publikováno v:
The Lancet Regional Health. Europe, Vol 46, Iss , Pp 101063- (2024)
Summary: Background: Prognostic factors for ambulatory oncology patients have been described, including Eastern Cooperative Oncology Group (ECOG), tumor stage and malnutrition. However, there is no firm evidence on which variables best predict mortal
Externí odkaz:
https://doaj.org/article/510c740dd59f414d89fc0806c8cb60c4
Autor:
Tomás Pascual, Aranzazu Fernandez-Martinez, Yash Agrawal, Adam D. Pfefferle, Nuria Chic, Fara Brasó-Maristany, Blanca Gonzàlez-Farré, Laia Paré, Guillermo Villacampa, Cristina Saura, Cristina Hernando, Montserrat Muñoz, Patricia Galván, Xavier Gonzàlez-Farré, Mafalda Oliveira, Miguel Gil-Gil, Eva Ciruelos, Patricia Villagrasa, Joaquín Gavilá, Aleix Prat, Charles M. Perou
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-11 (2024)
Abstract In this study, we performed genomic analyses of cell cycle and tumor microenvironment changes during and after ribociclib and letrozole or chemotherapy in the CORALLEEN trial. 106 women with untreated PAM50-defined Luminal B early breast can
Externí odkaz:
https://doaj.org/article/3f189cf1ef8a4f74a950d11ff22079b9
Autor:
Benedetta Conte, Fara Brasó-Maristany, Adela Rodríguez Hernández, Tomás Pascual, Guillermo Villacampa, Francesco Schettini, Maria J. Vidal Losada, Elia Seguí, Laura Angelats, Isabel Garcia-Fructuoso, Raquel Gómez-Bravo, Natàlia Lorman-Carbó, Laia Paré, Mercedes Marín-Aguilera, Olga Martínez-Sáez, Barbara Adamo, Esther Sanfeliu, Beatrice Fratini, Claudette Falato, Núria Chic, Ana Vivancos, Patricia Villagrasa, Johan Staaf, Joel S. Parker, Charles M. Perou, Aleix Prat
Publikováno v:
EBioMedicine, Vol 102, Iss , Pp 105043- (2024)
Summary: Background: Early-stage triple-negative breast cancer (TNBC) displays clinical and biological diversity. From a biological standpoint, immune infiltration plays a crucial role in TNBC prognosis. Currently, there is a lack of genomic tools ai
Externí odkaz:
https://doaj.org/article/e280cec22ed2498189d321ebd159a946
Autor:
Marta Palafox, Laia Monserrat, Meritxell Bellet, Guillermo Villacampa, Abel Gonzalez-Perez, Mafalda Oliveira, Fara Brasó-Maristany, Nusaibah Ibrahimi, Srinivasaraghavan Kannan, Leonardo Mina, Maria Teresa Herrera-Abreu, Andreu Òdena, Mònica Sánchez-Guixé, Marta Capelán, Analía Azaro, Alejandra Bruna, Olga Rodríguez, Marta Guzmán, Judit Grueso, Cristina Viaplana, Javier Hernández, Faye Su, Kui Lin, Robert B. Clarke, Carlos Caldas, Joaquín Arribas, Stefan Michiels, Alicia García-Sanz, Nicholas C. Turner, Aleix Prat, Paolo Nuciforo, Rodrigo Dienstmann, Chandra S. Verma, Nuria Lopez-Bigas, Maurizio Scaltriti, Monica Arnedos, Cristina Saura, Violeta Serra
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-20 (2022)
CDK4/6 inhibitor resistance is common in breast cancer. Here, the authors show that p16 overexpression may be linked to reduced efficacy of CDK4/6 inhibition, and show that the combination with PI3K inhibitors may increase anti-tumour effects.
Externí odkaz:
https://doaj.org/article/c3a330e420d34dc992aab0ec2b80986a
Autor:
Guillermo Villacampa, Dhrusti Patel, Haiyan Zheng, Jessica McAleese, Jan Rekowski, Olga Solovyeva, Zhulin Yin, Christina Yap
Publikováno v:
EClinicalMedicine, Vol 60, Iss , Pp 102020- (2023)
Summary: Background: The paradigm of early phase dose-finding trials has evolved in recent years. Innovative dose-finding designs and protocols which combine phases I and II are becoming more popular in health research. However, the quality of these
Externí odkaz:
https://doaj.org/article/7c0f5bbeacc64de39037ba47262ab652
Autor:
Leticia De Mattos-Arruda, Javier Cortes, Juan Blanco-Heredia, Daniel G. Tiezzi, Guillermo Villacampa, Samuel Gonçalves-Ribeiro, Laia Paré, Carla Anjos Souza, Vanesa Ortega, Stephen-John Sammut, Pol Cusco, Roberta Fasani, Suet-Feung Chin, Jose Perez-Garcia, Rodrigo Dienstmann, Paolo Nuciforo, Patricia Villagrasa, Isabel T. Rubio, Aleix Prat, Carlos Caldas
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-10 (2021)
Abstract The biology of breast cancer response to neoadjuvant therapy is underrepresented in the literature and provides a window-of-opportunity to explore the genomic and microenvironment modulation of tumours exposed to therapy. Here, we characteri
Externí odkaz:
https://doaj.org/article/206a008b2ff14604b0c18a4e4d55bbec
Autor:
Gloria Iacoboni, Guillermo Villacampa, Nuria Martinez‐Cibrian, Rebeca Bailén, Lucia Lopez Corral, Jose M. Sanchez, Manuel Guerreiro, Ana Carolina Caballero, Alberto Mussetti, Juan‐Manuel Sancho, Rafael Hernani, Pau Abrisqueta, Carlos Solano, Anna Sureda, Javier Briones, Alejandro Martin Garcia‐Sancho, Mi Kwon, Juan Luis Reguera‐Ortega, Pere Barba, GETH, GELTAMO Spanish Groups
Publikováno v:
Cancer Medicine, Vol 10, Iss 10, Pp 3214-3223 (2021)
Abstract Tisagenlecleucel (tisa‐cel) is a second‐generation autologous CD19‐targeted chimeric antigen receptor (CAR) T‐cell therapy approved for relapsed/refractory (R/R) large B‐cell lymphoma (LBCL). The approval was based on the results o
Externí odkaz:
https://doaj.org/article/c5750ec54d2047259016169d6fdbead9